Zoetis Inc.
81.03USD
-0.9700 (-1.18%)
Computing valuation metrics…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ZTS.
Valuation
P/E (TTM)
12.80x
P/E (Forward)
12.38x
EV/EBITDA
10.10x
EV/Revenue
4.31x
P/S (TTM)
3.52x
P/B
10.64x
FCF Yield
6.92%
Dividend Yield
2.62%
Gross Margin
71.54%
Operating Margin
40.72%
Net Margin
27.49%
Peer Comparison — Drug Manufacturers - Specialty & Generic
| Company | Mkt Cap | P/E | EV/EBITDA | FCF Yield | Rev Growth | Div Yield |
|---|---|---|---|---|---|---|
| ZTSZoetis Inc. | $33.48B | 12.80x | 10.10x | 6.92% | -0.24% | 2.62% |
| TEVATeva Pharmaceutical Industries Limited | $45.96B | 65.68x | 13.86x | 4.83% | -0.80% | 0.00% |
Subject metrics from SEC filings where available; peer metrics from cached market data.
| $25.20B |
| 21.04x |
| 15.06x |
| 2.21% |
| -1.90% |
| 0.00% |
| VTRSViatris Inc. | $20.67B | — | 7.64x | 12.95% | 4.90% | 2.67% |
| HIMSHims & Hers Health, Inc. | $6.47B | — | — | 13.14% | 38.20% | 0.00% |
| KNSAKiniksa Pharmaceuticals International, plc | $5.90B | 77.51x | 53.60x | 2.14% | 55.40% | 0.00% |
| LQDALiquidia Corporation | $3.82B | 30.68x | 21.89x | 1.95% | 1842.70% | 0.00% |
| RGCRegencell Bioscience Holdings Limited | $3.80B | — | — | -0.08% | — | 0.00% |
| AMLXAmylyx Pharmaceuticals, Inc. | $3.41B | — | — | -2.26% | — | 0.00% |